Evidence map›Paper›PMID 26309402›Full record

ArticleDrug design, development and therapy2015

Therapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate-loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinoma.

Michael Hrynyk, Jordon P Ellis, Fiona Haxho, Stephanie Allison, Joseph Am Steele, Samar Abdulkhalek, Ronald J Neufeld, Myron R Szewczuk

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Michael HrynykDepartment of Chemical Engineering, Queen's University, Kingston, ON, Canada.
Jordon P EllisDepartment of Chemical Engineering, Queen's University, Kingston, ON, Canada.
Fiona HaxhoDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Stephanie AllisonDepartment of Chemical Engineering, Queen's University, Kingston, ON, Canada.
Joseph Am SteeleDepartment of Chemical Engineering, Queen's University, Kingston, ON, Canada.
Samar AbdulkhalekDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Ronald J NeufeldDepartment of Chemical Engineering, Queen's University, Kingston, ON, Canada.
Myron R SzewczukDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Queen's University · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

Poly (lactic-co-glycolic acid) (PLGA) copolymers have been extensively used in cancer research. PLGA can be chemically engineered for conjugation or encapsulation of drugs in a particle formulation. We reported that oseltamivir phosphate (OP) treatment of human pancreatic tumor-bearing mice disrupted the tumor vasculature with daily injections. Here, the controlled release of OP from a biodegradable PLGA cylinder (PLGA-OP) implanted at tumor site was investigated for its role in limiting tumor neovascularization, growth, and metastasis. PLGA-OP cylinders over 30 days in vitro indicated 20%-25% release profiles within 48 hours followed by a continuous metronomic low dose release of 30%-50% OP for an additional 16 days. All OP was released by day 30. Surgically implanted PLGA-OP containing 20 mg OP and blank PLGA cylinders at the tumor site of heterotopic xenografts of human pancreatic PANC1 tumors in RAGxCγ double mutant mice impeded tumor neovascularization, growth rate, and spread to the liver and lungs compared with the untreated cohort. Xenograft tumors from PLGA and PLGA-OP-treated cohorts expressed significant higher levels of human E-cadherin with concomitant reduced N-cadherin and host CD31(+) endothelial cells compared with the untreated cohort. These results clearly indicate that OP delivered from PLGA cylinders surgically implanted at the site of the solid tumor show promise as an effective treatment therapy for cancer.

Indexed as

Drug CarriersNeovascularization, PathologicAbsorbable ImplantsAngiogenesis InhibitorsAnimalsAntigens, CDCadherinsCarcinomaCell Line, TumorChemistry, PharmaceuticalDrug ImplantsInterleukin Receptor Common gamma SubunitLiver NeoplasmsLung NeoplasmsMice, Inbred NODMice, KnockoutAngiogenesis InhibitorsAntigens, CDCadherinsCDH1 protein, humanCDH2 protein, humanDrug CarriersDrug ImplantsIl2rg protein, mouseInterleukin Receptor Common gamma SubunitOseltamivirPlatelet Endothelial Cell Adhesion Molecule-1Polyethylene Glycolsmetastasisoseltamivir phosphatepancreatic cancerPLGAtumor neovascularization

Identifiers

PMID26309402
PMCPMC4539083
OpenAlexW2116491845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.